(Total Views: 413)
Posted On: 11/27/2020 10:54:23 AM
Post# of 36542
If the COVID-SeroKlir test (https://www.cnbc.com/2020/11/25/fda-clears-a-new-generation-of-covid-antibody-test-designed-to-tell-how-well-someone-is-protected-against-the-virus.html) can minutely measure a person’s antibody levels, this is a game changer. I envision a vaccine trial where all the double blind participants are first tested. (Present vaccine trials would have to reset with new participants.) Then after the final dose (1or 2 shots), a second test is administered to establish a base line. The placebo group would naturally be at zero and the vaccine recipients would have their initial personal antibody base level set. During the trial, when a participant gets Covid symptoms, they would be separated, treated, and monitored for Covid symptoms/antibody relationships.
After a month or two, all non-symptomatic participants would be retested for antibody levels. Any placebo persons that had Covid antibodies would be separated and studied to see if they have a natural Covid-19 immunity, or were just unaware (asymmetric) that they had contracted the virus.
Vaccinated participants would have one of three results. The antibodies will have either increased, decreased or remained the same. Now the tough part, finding out why. I see several possibilities.
The person physiology interacted with the vaccine causing an antibody level change.
The vaccine effectiveness change the antibody level.
The participant came in contact with the active Covid virus and the invasion was successfully repelled. (Best case)
The participant contracted Covid, but the vaccine only lowered or masked the symptoms making the person unaware that they were infected. (Worst case)
As a mere layman, I do not know if the Worst Case scenario is even possible, but if a vaccine would just mask the Covid symptoms, making a person asymmetric, who then unknowing interacts with the general public… I find that troubling.
I hope that each drug company has a vaccine expert that has considered this possibility and has collected definitive date (hopefully) ruling it out. And that they will provide this date to the EUA board during the approval process.
After a month or two, all non-symptomatic participants would be retested for antibody levels. Any placebo persons that had Covid antibodies would be separated and studied to see if they have a natural Covid-19 immunity, or were just unaware (asymmetric) that they had contracted the virus.
Vaccinated participants would have one of three results. The antibodies will have either increased, decreased or remained the same. Now the tough part, finding out why. I see several possibilities.
The person physiology interacted with the vaccine causing an antibody level change.
The vaccine effectiveness change the antibody level.
The participant came in contact with the active Covid virus and the invasion was successfully repelled. (Best case)
The participant contracted Covid, but the vaccine only lowered or masked the symptoms making the person unaware that they were infected. (Worst case)
As a mere layman, I do not know if the Worst Case scenario is even possible, but if a vaccine would just mask the Covid symptoms, making a person asymmetric, who then unknowing interacts with the general public… I find that troubling.
I hope that each drug company has a vaccine expert that has considered this possibility and has collected definitive date (hopefully) ruling it out. And that they will provide this date to the EUA board during the approval process.
(1)
(0)Scroll down for more posts ▼
